Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy

Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy

BackgroundTissue covalently closed circular DNA (cccDNA) can reflect the activity of HBV replication. However, it is impractical to assess intrahepatic cccDNA in every outpatient. Serum pregenome RNA (pgRNA) is transcribed from intrahepatic cccDNA and may reflect the activity of intrahepatic cccDNA....

Full description

Bibliographic Details
Main Authors:	Yachao Tao, Menglan Wang, Juan Liao, Xing Cheng, Min He, Dongmei Zhang, Taoyou Zhou, Jie Chen, Enqiang Chen, Hong Tang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Medicine
Subjects:	pregenome RNA chronic hepatitis B HBV DNA hepatitis B e antigen seroconversion nucleos(t)ide analogs
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.787770/full

Similar Items

Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B
by: Fa-Da Wang, et al.
Published: (2022-06-01)

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss
by: I-Chin Wu, et al.
Published: (2021-05-01)

Stability of hepatitis B virus pregenomic RNA in plasma specimens under various temperatures and storage conditions
by: Pakkapon Rattanachaisit, et al.
Published: (2021-04-01)

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice
by: Mingfan Geng, et al.
Published: (2017-09-01)

A Study on Pregenomic RNA and Factors Related to Hepatitis B Virus Infection Based on Real World
by: Hao-Zhen Yan, et al.
Published: (2022-06-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)

Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy
by: Ying Xu, et al.
Published: (2017-09-01)

Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B
by: E K Ibragimov, et al.
Published: (2019-02-01)

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
by: Yi-Cheng Chen, et al.
Published: (2020-05-01)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
by: Camila V Pereira, et al.
Published: (2016-04-01)

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs
by: Tao Li, et al.
Published: (2018-01-01)

Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Meng-Ju Lin, et al.
Published: (2023-07-01)

Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
by: Ayato Murata, et al.
Published: (2022-05-01)

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
by: Yandi Xie, et al.
Published: (2023-06-01)

Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy
by: Er-Mei Li, et al.
Published: (2021-08-01)

Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
by: Ying-Nan Tsai, et al.
Published: (2024-01-01)

Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
by: Lanqing Li, et al.
Published: (2023-06-01)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
by: Zhang C, et al.
Published: (2016-03-01)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
by: Sang Kyung Jung, et al.
Published: (2015-03-01)

Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy
by: Chih-Lin Lin, et al.
Published: (2020-10-01)

Baseline Circulating miR-125b Levels Predict a High FIB-4 Index Score in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Treatment
by: Jyun-Yi Wu, et al.
Published: (2022-11-01)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
by: Guangjun Song, et al.
Published: (2023-11-01)

The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
by: Jae Min Park, et al.
Published: (2021-09-01)

Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued
by: Liao G, et al.
Published: (2022-04-01)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
by: Anna Maisa, et al.
Published: (2021-05-01)

The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights
by: Fabrizio Fabrizi, et al.
Published: (2023-02-01)

Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study
by: Li Y, et al.
Published: (2021-08-01)

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
by: Jing Zhao, et al.
Published: (2023-03-01)

Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent
by: Jing‐Houng Wang, et al.
Published: (2019-11-01)

NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
by: E. A. Elpaeva, et al.
Published: (2015-12-01)

Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis
by: Yuhao Yao, et al.
Published: (2022-11-01)

Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence
by: Akinobu Takaki, et al.
Published: (2015-07-01)

Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance
by: Hung-Chih Yang, et al.
Published: (2014-01-01)

Editorial: Hepatitis B virus and host interactions in liver diseases
by: Yuen Gao, et al.
Published: (2023-05-01)

Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus‐related hepatocellular carcinoma after surgical resection: A multicenter study
by: Weili Qi, et al.
Published: (2021-12-01)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01)

Strategy to control occupational risk for Hepatitis B: impact on the vaccination and seroconversion rates in dentistry students
by: Daniela Nunes NOGUEIRA, et al.
Published: (2018-03-01)